Clinical trials: Cognitive Deficits, Mild
Alzheimer Disease
A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD
This is a Phase 2A multi-center, randomized, double blind, placebo-controlled, parallel group study of varoglutamstat, with a stage gate to Phase 2B.
- Trial name
- VIVA-MIND (NCT03919162)
- Testing
- PQ912
- Where
- 22 sites in United States
- Volunteers
- 112 people
- Sponsor
- Vivoryon Therapeutics N.V.
Dementia, Mild Cognitive Impairment
In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment
This study aims to develop and evaluate new in-home supportive technology that is designed to alleviate anxiety, burden, and loneliness in spousal and familial caregivers of individuals with Alzheimer's disease, other dementias…
- Conditions
- Dementia, Mild Cognitive Impairment, Alzheimer Disease
- Trial name
- NCT04206670
- Testing
- In-Home Technology System and Questionnaires, Waiting Control In-Home Technology System and Questionnaires
- Where
- United States
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- University of California, Berkeley
Dementia, Mild Cognitive Impairment
Repetitive Transcranial Magnetic Stimulation for Dementia
The purpose is to is to study if repetitive transcranial magnetic stimulation (rTMS) improves cognitive function in patients with neurodegenerative conditions which may manifest as mild to moderate cognitive impairment and, in…
- Trial name
- rTMS for demen (NCT02621424)
- Testing
- RTMS
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- VA Office of Research and Development
Alzheimer's Disease, Cognitive Impairment
Effect of EGb761® on Brain Glucose Metabolism in Three Groups of Elderly Defined by Cognitive Functions
The aim of the study is to evaluate the effect of EGb761®, in comparison to placebo, on cerebral glucose metabolism, in three groups of elderly patients: newly diagnosed mild Alzheimer's disease (AD), memory complaint patients…
- Trial name
- NCT00814346
- Testing
- EGb761®
- Where
- 8 sites in France
- Volunteers
- 49 people
- Sponsor
- Ipsen
Mild Cognitive Impairment
Using fMRI-guided TMS to Increase Central Executive Function in Older Adults (MCI_Sub)
This is an administrative supplement to an existing project "Using fMRI-guided TMS to increase central executive function in older adults: NCT02767323" This award allows extending our existing fMRI-TMS paradigm to patients with a…
- Trial name
- MCI_Sub (NCT04176406)
- Testing
- rTMS
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Duke University
Mild Cognitive Impairment, Primary Progressive Aphasia
Home-based tDCS in Frontotemporal Dementia or Alzheimer's Disease
The primary objective of this research is to evaluate the effects of non-invasive brain stimulation and computerized cognitive training on executive functioning in individuals with Primary Progressive Aphasia (PPA), mild…
- Conditions
- Mild Cognitive Impairment, Primary Progressive Aphasia, Dementia
- Trial name
- NCT05978804
- Testing
- Computerized Cognitive Training, Active tDCS (tDCS) on DLPFC
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Johns Hopkins University
Mild Cognitive Impairment
Rehabilitation of Attention in Patients With MCI and Brain Subcortical Vascular Changes Using the APT-II
Background: Subcortical Vascular Dementia (VaD), consequent to deep brain small vessel disease (SVD), is the most frequent form of VaD.
- Trial name
- RehAtt (NCT02033850)
- Testing
- Attention Process Training-II
- Where
- Italy
- Volunteers
- 46 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Mild Cognitive Impairment, Alzheimer's Disease
Reducing Risk for Alzheimer's Disease in High-Risk Women Through Yogic Meditation Training
The purpose of this pilot study will be to test whether Kundalini yoga (KY) and Kirtan Kriya (KK) yogic meditation is superior to Memory Enhancement Training (MET) for improving cognitive functioning, health (including…
- Trial name
- NCT03503669
- Testing
- Memory Training, Kundalini yoga and meditation
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of California, Los Angeles
Mild Cognitive Impairment
Rhythmic Light Therapy for Alzheimer's Disease Patients
The investigator will investigate how light delivering 40 hertz (Hz) affects subjective sleep and cognition in a controlled laboratory study.
- Trial name
- NCT05015478
- Testing
- Tailored Rhythmic Lighting Intervention
- Where
- 2 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Cognitive Dysfunction, Alzheimer's Disease
A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities
The primary objective of the study is to assess the safety impact of continuing aducanumab dosing in asymptomatic Amyloid-related Imaging Abnormalities (ARIA) in participants with mild cognitive impairment (MCI) due to…
- Trial name
- EVOLVE (NCT03639987)
- Testing
- Aducanumab
- Where
- 22 sites in United States
- Volunteers
- 52 people
- Sponsor
- Biogen
Alzheimer Disease, Mild Cognitive Impairment
Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET Scans
This study will investigate the performance of physician readers trained to read florbetapir-PET scans using electronic media training.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Neurodegenerative Diseases
- Trial name
- NCT01550549
- Testing
- florbetapir F 18
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Mild Cognitive Impairment, Healthy Aging
SHARE(D) Stage II: Alzheimer's Risk Disclosure Protocol Piloting
The goal of this study is to test efficacy and safety of person-centered, culturally-informed protocols for disclosure of different combinations of Alzheimer's dementia risk factors.
- Trial name
- SHARE(D) (NCT04309500)
- Testing
- Personalized DAT Risk Disclosure Protocol
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Alzheimer's Disease
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
The purpose of this Phase 1/Phase 2 study is to evaluate how the body handles the drug and the drug's effect on the body of participants with mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) or mild AD and who test…
- Trial name
- NCT01561430
- Testing
- LY2886721
- Where
- 34 sites in United States, Italy and 3 more
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company
Amnestic Mild Cognitive Impairment, Alzheimer's Disease
Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)
This study consists of two parts, Part 1 and Part 2. Part 1 assesses the efficacy and safety of verubecestat (MK-8931) compared with placebo administered for 104 weeks in the treatment of amnestic mild cognitive impairment (aMCI)…
- Conditions
- Amnestic Mild Cognitive Impairment, Alzheimer's Disease, Prodromal Alzheimer's Disease
- Trial name
- APECS (NCT01953601)
- Testing
- Verubecestat 12 mg (Parts 1 and 2), Verubecestat 40 mg (Parts 1 and 2)
- Volunteers
- 1,454 people
- Sponsor
- Merck Sharp & Dohme LLC
Mild Cognitive Impairment, Mild Dementia
A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)
The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance in participants with Alzheimer's Disease.
- Conditions
- Mild Cognitive Impairment, Mild Dementia, Alzheimer's Disease
- Trial name
- NCT05619692
- Testing
- SAGE-718
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 174 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Mild Cognitive Impairment, Dementia; Alzheimer's Type (Etiology)
STIM+: PET Biomarker Education & Disclosure
When dementia is caused by AD, we refer to it as dementia of the Alzheimer's Type (DAT). The greatest risk factor for Alzheimer's Disease (AD) and DAT is advancing age, but DAT is not a normal part of aging.
- Trial name
- STIM+ (NCT04818255)
- Testing
- PET Biomarker Disclosure
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- University of Michigan
Depression Mild, Depressive Disorder, Major
Cognitive Fitness for Depression in Older Adults
This research is being done to determine if computerized administered cognitive fitness activities will improve thinking and depression in older depressed adults who are being treated with antidepressants.
- Conditions
- Depression Mild, Depressive Disorder, Major, Mild Cognitive Impairment
- Trial name
- NCT04790630
- Testing
- Computerized Cognitive Remediation of Executive Functioning (CCR-EF), Active Control
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- UConn Health
Polypharmacy, Alzheimer's Disease and Related Dementias
ALIGN: Aligning Medications With What Matters Most (Demonstration)
The goal of this clinical trial is to test the effectiveness of a pharmacist-led, primary care-based de-prescribing intervention for people living with dementia (PLWD) and the person's care partners.
- Conditions
- Polypharmacy, Alzheimer's Disease and Related Dementias, Mild Cognitive Impairment
- Trial name
- NCT06335953
- Testing
- Pharmacist-led deprescribing intervention
- Where
- United States
- Volunteers
- 474 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Advance Care Planning, Telemedicine
A Telehealth Advance Care Planning Intervention in Those With Mild Cognitive Impairment or Unrecognized Dementia
The purpose of this study is to pilot test a telehealth Advance Care Planning (ACP) intervention among those with either mild cognitive impairment (MCI) or unrecognized dementia.
- Conditions
- Advance Care Planning, Telemedicine, Mild Cognitive Impairment, Unrecognized Dementia
- Trial name
- ACP (NCT04912245)
- Testing
- Telehealth visit
- Where
- 7 sites in United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Mild Cognitive Impairment
Candesartan's Effects on Alzheimer's Disease And Related Biomarkers
This study is intended to investigate the safety of candesartan, a blood pressure medication, in non-hypertensive individuals who have mild cognitive impairment (MCI) due to Alzheimer's disease and its effect on disease…
- Trial name
- CEDAR (NCT02646982)
- Testing
- Candesartan
- Where
- 2 sites in United States
- Volunteers
- 77 people
- Sponsor
- Emory University